MiCan Technologies Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
20
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$1.77M
- Investors
-
19
MiCan Technologies General Information
Description
Developer of cell production technology designed to enable scalable manufacturing of standardised blood cells for testing applications. The company offers immortalised blood cell production and mass manufacturing capabilities for monocyte activation testing, enabling pharmaceutical and research organizations to conduct pyrogen testing without animal-based methods.
Contact Information
Website
www.micantechnologies.comCorporate Office
- Kyoto-University Katsura Venture Plaza, Kyoto Research Institute
- 1-36 Ohara, Goryo, Nishikyo-ku
- Kyoto, 615-8245
- Japan
Corporate Office
- Kyoto-University Katsura Venture Plaza, Kyoto Research Institute
- 1-36 Ohara, Goryo, Nishikyo-ku
- Kyoto, 615-8245
- Japan
MiCan Technologies Timeline
MiCan Technologies Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 12. Later Stage VC | 24-Jan-2025 | $1.77M | Completed | Generating Revenue | ||
| 11. Later Stage VC | 01-Jan-2024 | Completed | Generating Revenue | |||
| 10. Accelerator/Incubator | Completed | Generating Revenue | ||||
| 9. Later Stage VC | 30-Jun-2023 | Completed | Generating Revenue | |||
| 8. Later Stage VC (Series B) | 10-Apr-2023 | Completed | Generating Revenue | |||
| 7. Accelerator/Incubator | 01-Jan-2022 | Completed | Generating Revenue | |||
| 6. Later Stage VC (Series A2) | 17-Sep-2021 | Completed | Generating Revenue | |||
| 5. Accelerator/Incubator | 01-Jan-2020 | Completed | Generating Revenue | |||
| 4. Early Stage VC (Series A) | 23-Aug-2019 | $1.49M | $1.54M | Completed | Generating Revenue | |
| 3. Accelerator/Incubator | $48.1K | Completed | Startup |
MiCan Technologies Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| B2 Preferred | ||||||||
| B3 Preferred | ||||||||
| B Preferred | ||||||||
| A2 Preferred | 2,910 | $413.51 | $413.51 | 1x | $413.51 | 14.43% | ||
| A Preferred | 2,955 | $343.53 | $343.53 | 1x | $343.53 | 14.65% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
MiCan Technologies Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
MiCan Technologies Patents
MiCan Technologies Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025249480-A1 | Novel human immortalized myeloid cells | Pending | 29-May-2024 | ||
| WO-2025205045-A1 | Method for producing cells susceptible to viral infection | Pending | 29-Mar-2024 | ||
| WO-2024090441-A1 | Single-round infectious particles of virus belonging to orthocoronavirus subfamily and antibody function evaluation method using said particles | Inactive | 24-Oct-2022 | ||
| JP-7902432-B2 | Evaluation method for antibody-dependent enhancement of infection response using pseudoviruses | Active | 27-May-2021 | ||
| EP-4349976-A1 | Method for evaluating antibody-dependent enhancement reaction using pseudovirus | Pending | 27-May-2021 | G01N33/56983 |
MiCan Technologies Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
MiCan Technologies Investors (19)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Chushin Venture Capital | Corporate Venture Capital | Minority | ||
| Minato | Corporation | Minority | ||
| Mitani Sangyo | Corporation | Minority | ||
| Osaka Small and Medium Business Investment & Consultation Company | Venture Capital | Minority | ||
| Senshu Ikeda Capital | Venture Capital | Minority |
MiCan Technologies FAQs
-
When was MiCan Technologies founded?
MiCan Technologies was founded in 2016.
-
Where is MiCan Technologies headquartered?
MiCan Technologies is headquartered in Kyoto, Japan.
-
What is the size of MiCan Technologies?
MiCan Technologies has 20 total employees.
-
What industry is MiCan Technologies in?
MiCan Technologies’s primary industry is Biotechnology.
-
Is MiCan Technologies a private or public company?
MiCan Technologies is a Private company.
-
What is the current valuation of MiCan Technologies?
The current valuation of MiCan Technologies is .
-
What is MiCan Technologies’s current revenue?
The current revenue for MiCan Technologies is .
-
How much funding has MiCan Technologies raised over time?
MiCan Technologies has raised $7.53M.
-
Who are MiCan Technologies’s investors?
Chushin Venture Capital, Minato, Mitani Sangyo, Osaka Small and Medium Business Investment & Consultation Company, and Senshu Ikeda Capital are 5 of 19 investors who have invested in MiCan Technologies.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
